Clinical trial NCT03643562: Niemann-Pick Type C Treatment With Adrabetadex for Symptoms of Brain and Nervous System
Official title: Open-label Evaluation of Adrabetadex in Patients With Neurologic Manifestations of Niemann-Pick Type C Disease (NPC)
Study type: INTERVENTIONAL
Overall status: TERMINATED
Phase: PHASE3
Conditions: Niemann-Pick Type C Disease
Keywords: Niemann-Pick
NPC
NPC Type 1 (NPC1)
Lead sponsor: Mandos LLC
Sponsor class: INDUSTRY
First posted: 2018-08-23
Enrollment: 27
Sex: ALL
Minimum age (years): 4
Standard ages: CHILD
ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Intervention model description: Continued treatment for children at least 4 years of age
Primary purpose: TREATMENT

Brief summary: This study was amended from expanded access to a clinical trial. Information will be collected about long-term safety and effectiveness of adrabetadex shots in the spine every 2 weeks.

Participants who were already taking adrabetadex will receive their stable dose. Participants who have not ever taken it will start by receiving 400 mg.

Participants will receive treatment every 2 weeks until their doctor finds it does not help them anymore, they withdraw, or the study is stopped for any reason. Participants will not receive additional study treatment after their participation in this protocol.


Eligibility criteria: Inclusion Criteria:

To be included in the study, a participant must meet the following criteria:

* Is male or female and at least 4 years of age at time of screening.
* Has a confirmed diagnosis of NPC and exhibits neurologic symptoms.
* Has written informed consent/assent to participate.
* Has the ability to undergo LP and IT drug administration.
* If taking miglustat (Zavesca®), must have been on a stable dose for the past 6 weeks and be willing to remain on a stable dose for the duration of participation in the study, or discontinue miglustat use at least 6 weeks before entry into the study (Day 1).
* If has a history of seizures, the condition is adequately controlled as per protocol requirements.
* Agrees to discontinue any investigational treatments (other than adrabetadex) for at least 1 month before first dose on Day 1.
* If engaging in heterosexual sex, agrees to use a protocol-defined method of contraception throughout the study, and until 30 days after completing the study.
* Has a responsible adult who the investigator determines is able and willing to comply with study requirements and a parent/guardian who will accompany the participant to study visits.

Exclusion Criteria:

Participants will be excluded from the study if they meet any of the following criteria:

* Weighs less than 15 kg.
* Has a history of hypersensitivity reactions to any product containing 2-hydroxypropyl-β-cyclodextrin (HP-β-CD) or has a history of hypersensitivity reactions or allergy to anesthesia/sedation.
* Has received treatment with any investigational product (other than adrabetadex) within 1 month prior to Day 1 of treatment.
* Is pregnant or nursing.
* Has systemic infection or uncontrolled psychosis.
* Has known history of a bleeding disorder.
* Has used anticoagulants within 2 months of entry into the study.
* Per protocol, or in the opinion of the investigator:

  1. has laboratory values that would preclude participation
  2. has suspected infection of the central nervous system (CNS)
  3. has a spinal deformity that could impact performance of repeated LPs
  4. has a serious skin infection in the lumbar region or evidence of obstructive or normal pressure hydrocephalus
  5. is unable to comply with the study requirements
  6. has a medical condition that might increase the risk of participation

Primary outcomes:
measure: Number of Participants With Treatment-Emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs)
timeFrame: Baseline up to Week 134
Secondary outcomes:
Other outcomes:
Locations:
city: Little Rock
country: United States
facility: University of Arkansas System
state: Arkansas
city: Loma Linda
country: United States
facility: Loma Linda University Health System
state: California
city: Los Angeles
country: United States
facility: Children's Hospital Los Angeles
state: California
city: Orange
country: United States
facility: Children's Hospital of Orange County
state: California
city: Aurora
country: United States
facility: Children's Hospital Colorado
state: Colorado
city: Washington
country: United States
facility: Children's National Hospital
state: District of Columbia
city: Atlanta
country: United States
facility: Rare Disease Research, LLC
state: Georgia
city: Chicago
country: United States
facility: Rush University Medical Center
state: Illinois
city: Saint Paul
country: United States
facility: Gillette Children's Specialty Healthcare
state: Minnesota
city: Las Vegas
country: United States
facility: Children's Specialty Center of Nevada
state: Nevada
city: New York
country: United States
facility: NYU Langone Medical Center
state: New York
city: Cincinnati
country: United States
facility: Cincinnati Children's Hospital Medical Center
state: Ohio
city: Portland
country: United States
facility: Oregon Health & Science University
state: Oregon
city: Nashville
country: United States
facility: The Children's Hospital at TriStar Centennial
state: Tennessee
city: Nashville
country: United States
facility: Vanderbilt University Medical Center
state: Tennessee
city: Austin
country: United States
facility: Dell Children's Medical Center of Central Texas
state: Texas
city: Roanoke
country: United States
facility: Carilion Medical Center, Carilion Clinic
state: Virginia
Study officials:
affiliation: Mandos LLC
name: Clinical Study Lead
role: STUDY_DIRECTOR
References: